Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Non-Current Debt (2016 - 2021)

Abvc Biopharma (ABVC) has disclosed Non-Current Debt for 6 consecutive years, with $650000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Non-Current Debt rose 422.51% year-over-year to $650000.0, compared with a TTM value of $650000.0 through Dec 2021, up 422.51%, and an annual FY2021 reading of $650000.0, up 422.51% over the prior year.
  • Non-Current Debt was $650000.0 for Q4 2021 at Abvc Biopharma, up from $104167.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $7.7 million in Q4 2018 and bottomed at $5388.0 in Q1 2019.
  • Average Non-Current Debt over 4 years is $1.9 million, with a median of $478231.0 recorded in 2020.
  • The sharpest move saw Non-Current Debt tumbled 99.87% in 2019, then skyrocketed 422.51% in 2021.
  • Year by year, Non-Current Debt stood at $7.7 million in 2018, then crashed by 94.5% to $425689.0 in 2019, then crashed by 70.78% to $124400.0 in 2020, then surged by 422.51% to $650000.0 in 2021.
  • Business Quant data shows Non-Current Debt for ABVC at $650000.0 in Q4 2021, $104167.0 in Q3 2021, and $236498.0 in Q2 2021.